“We are very pleased to be able to cover three additional countries in the middle of Europe through a strong distribution partner. We will start to train their team and hand over existing opportunities in the next few weeks. We are proud to have such a large European distribution footprint just within 12 months after starting to execute on our new strategy last year. This agreement is great proof of the strong value proposition of ASTar,” said Thomas Fritz, CCO at Q-linea.

“Rapid AST is an area that we have been looking to add to our portfolio as we have identified it as a key need for hospitals to improve therapy and patient outcome. ASTar is the preferred choice for us thanks to its ease of use, broad antibiotic coverage and technology, which is closest to the gold standard of broth microdilution-based susceptibility testing,” said Fabienne Steens, CEO at Biomedical Diagnostics.

About ASTar Instrument and ASTar BC G- Kit
ASTar Instrument and ASTar BC G- Kit already deliver the broadest answer regarding the combination of the number of antibiotics and the number of double dilution steps of each antibiotic, in a single analysis for gram-negative bacteria. The test enables the analysis of gram-negative bacteria, including difficult-to-grow so-called fastidious bacteria, which satisfies the need for rapid and comprehensive results to support optimal treatment decisions.

ASTar Instrument and ASTar BC G- Kit are CE-marked but not FDA 510(k)-cleared and not available for sale in the United States.